GC Cell: "Full Phase 1a Data on CAR-NK Therapy to Be Released by Year-End"
Interim Results to Be Presented at International Academic Conference
GC Cell will present interim results from the Phase 1a trial of GCC2005, an allogeneic CAR-NK cell therapy targeting refractory T-cell lymphoma, at an international academic event specializing in lymphoma. The company will share with Korean lymphoma experts data released at the American Society of Hematology (ASH) annual meeting last year and plans to announce the full Phase 1a data by the end of this year.
On October 28, GC Cell said it will present the development process for GCC2005 and interim Phase 1a results at the international academic event "2026 KLWP-EBML," held to mark the 20th anniversary of the Lymphoma Working Party of the Korean Society of Hematology. The presentation will be given by Professor Ko Young-il of Seoul National University Hospital.
GCC2005 is an allogeneic CAR-NK cell therapy targeting the CD5 protein. It is being developed as an "off-the-shelf" treatment that can be manufactured in advance using NK cells from another person. GC Cell gave an oral presentation on interim Phase 1a results at ASH 2025 last December. At the time, five of eight patients with relapsed or refractory NK/T-cell lymphoma who had received at least three prior lines of treatment responded, resulting in an objective response rate of 62.5%. Three of those patients achieved complete remission, with no detectable cancer.
GC Cell is currently conducting a Phase 1b trial in Korea, aiming to develop a first-in-class drug. It plans to present the full Phase 1a data at a major international medical conference by the end of this year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
GC Cell CEO Won Seong-yong said, "We are continuing discussions with experts by sharing clinical data and development updates at major conferences in Korea and abroad. We will advance the ongoing Phase 1b trial without disruption and move toward global development."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.